Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an ...

Howard Smith’s urologist told him his prostate cancer was not the kind you die with: “It’s the one that’s going to kill you.” ...

Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this ...

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer ...

The world’s first major trial of a personalised therapeutic cancer vaccine has been hailed a ‘foundational shift’ in how we ...

Young adult cancer survivors face gaps in follow-up care caused by factors including geographic mobility and insurance changes, according to an analysis by UTHealth Houston researchers.

Msd announced today that the European Commission has approved pembrolizumab in combination with enfortumab vedotin, as neoadjuvant treatment and subsequently, after radical cystectomy, as adjuvant ...

The RAS Initiative Advances New Hope for Patients With Cancer - National Cancer Institute / Anthony Letai, cancer, Cancer Cells, Dana-Farber Cancer Institute, ...

In alignment with its corporate mission to give back to the community, Sea Bags today announced a new Breast Cancer ...

Dana-Farber’s new 10-story hospital will be at the former site of the Joslin Diabetes Center and connect to Beth Israel ...

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ...